

type of report	Current report
number	31/2012
company	PHARMENA

Suspension of the Issue of series C bearer ordinary shares

The Management Board of Pharmena S.A. informs that on 3rd July 2012, a resolution was adopted on suspension of the Issue of not more than 1,100,000 of the Company's series C bearer ordinary shares until the nearest Extraordinary General Meeting.

The Management Board of the Issuer, after consulting Lead Manager and Financial Advisor, submitted the Supervisory Board a proposal to suspend the issue of series C shares. On 3rd July 2012, the Supervisory Board responded positively the said proposal of the Management Board.

A the same time, the Management Board of the Issuer informs that the Supervisory Board has requested it to immediately convene an Extraordinary General Meeting, purpose of which will include a decision on the resolution no. 16 adopted during Ordinary General Meeting of 14th May 2012 on the issue of series C shares.

Additionally, the Management Board informs that the Supervisory Board has consented to the Management Board incurring liabilities in the form of a loan up to 800,000 USD in order to finalise clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA. The Company intends to allocate the funds obtained in the above described manner to the completion of the process of production of tablets containing active substance 1-MNA and to carrying out bioavailability testing of 1-MNA, as a continuation of clinical trials on anti-atherosclerosis medicinal product 1-MNA.

The information is made public due to the fact that the goal of public offering of series C shares is to obtain funds on further clinical trials on anti-atherosclerosis medicinal product 1-MNA, which results may have significant influence on the Issuer's financial and economic situation in the future.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wiczorkowska – Vice President of the Board